For this open-label , non-comparative , multicentre , phase 2 study , eligible adult patients with advanced soft-tissue sarcomas , who had previously received doxorubicin-based chemotherapy and were able to receive trabectedin , were enrolled from 14 centres of the French Sarcoma Group .